Omega Funds | Activity

Investment

Led/participated in Vaderis Therapeutics $152.5M Series B financing to initiate the global Phase 3 HEROIC study for hereditary hemorrhagic telangiectasia.

Vaderis Therapeutics

Vaderis Therapeutics Omega Funds

fiercebiotech.comAUG 13, 2026

AUG 13, 2026

Milestone

Baxdrostat (Baxfendy), originating from Omega portfolio company CinCor Pharma, was approved in the US as the first aldosterone synthase inhibitor for hypertension.

CinCor Pharma

CinCor Pharma Omega Funds

astrazeneca.comMAY 18, 2026

MAY 18, 2026

Podcast

Founder Otello Stampacchia discussed Europe's biotech investment crisis on The Long Run podcast.

Otello Stampacchia on The Long Run

Omega Funds

timmermanreport.comMAR 2026

MAR 2026

Investment

Participated in Alveus Therapeutics oversubscribed Series A, bringing total financing to $197M for obesity and metabolic disease therapies.

Alveus Therapeutics

Alveus Therapeutics Omega Funds

alveustx.comFEB 24, 2026

FEB 24, 2026

Investment

Launched Caldera Therapeutics with $112.5M financing and first subjects dosed in a Phase 1 trial for a bispecific antibody targeting inflammatory bowel disease.

Caldera Therapeutics

Caldera Therapeutics Omega Funds

businesswire.comJAN 14, 2026

JAN 14, 2026

Investment

Backed Spiro Medical's $67M Series A financing for an asthma neuromodulation device.

Spiro Medical

Spiro Medical Omega Funds

fiercebiotech.comJAN 8, 2026

JAN 8, 2026

Investment

Backed Protego Biopharma oversubscribed $130M Series B financing to advance its AL amyloidosis program into a pivotal study.

Protego Biopharma

Protego Biopharma Omega Funds

protegobio.comDEC 1, 2025

DEC 1, 2025

New Fund

Closed Omega Fund VIII at $647M, oversubscribed against a $600M target, to continue investing in and creating life sciences companies.

Omega Fund VIII

Omega Funds

businesswire.comJUL 21, 2025

JUL 21, 2025

Investment

Launched Windward Bio with a $200M Series A financing to develop a long-acting anti-TSLP antibody for asthma and COPD.

Windward Bio

Windward Bio Omega Funds

globenewswire.comJUN 2025

JUN 2025

Press

Founder Otello Stampacchia spoke to STAT News about headwinds facing the biotech industry and the outlook for the sector.

Otello Stampacchia on biotech industry headwinds (STAT News)

Omega Funds

statnews.comAPR 7, 2025

APR 7, 2025

Omega Funds Activity

Led/participated in Vaderis Therapeutics $152.5M Series B financing to initiate the global Phase 3 HEROIC study for hereditary hemorrhagic telangiectasia.

Portfolio company Replimune received FDA approval for a new engineered viral immunotherapy for treatment-resistant advanced melanoma.

Baxdrostat (Baxfendy), originating from Omega portfolio company CinCor Pharma, was approved in the US as the first aldosterone synthase inhibitor for hypertension.

Founder Otello Stampacchia discussed Europe's biotech investment crisis on The Long Run podcast.

Participated in Alveus Therapeutics oversubscribed Series A, bringing total financing to $197M for obesity and metabolic disease therapies.

Launched Caldera Therapeutics with $112.5M financing and first subjects dosed in a Phase 1 trial for a bispecific antibody targeting inflammatory bowel disease.

Backed Spiro Medical's $67M Series A financing for an asthma neuromodulation device.

Backed Protego Biopharma oversubscribed $130M Series B financing to advance its AL amyloidosis program into a pivotal study.

Closed Omega Fund VIII at $647M, oversubscribed against a $600M target, to continue investing in and creating life sciences companies.

Launched Windward Bio with a $200M Series A financing to develop a long-acting anti-TSLP antibody for asthma and COPD.

Founder Otello Stampacchia spoke to STAT News about headwinds facing the biotech industry and the outlook for the sector.